This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

59/100

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Tau biomarkers

Topic: Brain proteins, microglia and lab models

Background and objectives α-Synuclein seed amplification assays (αSAAs) can improve the diagnosis of synucleinopathies and detect α-synuclein (αSyn) copathology in vivo in clinical practice. We aimed to evaluate the diagnostic performance of αSAA for detecting αSyn in CSF for diagnosing dementia with Lewy bodies (DLB) in a clinical cohort of cognitively impaired individuals. We explored how the coexistence of Alzheimer disease (AD) and αSyn pathology influences biomarker levels and clinical profiles.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Esteller-Gauxax, D., Pérez Millan, A., Sarto, J., Puey, R., Guillén Soley, N., Tort-Merino, A., et al. (2025). α-Synuclein Seed Amplifications Assay in a Cohort With Cognitive Impairment: Performance and Interactions With CSF and Plasma Biomarkers. Neurology. https://doi.org/10.1212/wnl.0000000000214040

Vancouver

Esteller-Gauxax D, Pérez Millan A, Sarto J, Puey R, Guillén Soley N, Tort-Merino A, et al. α-Synuclein Seed Amplifications Assay in a Cohort With Cognitive Impairment: Performance and Interactions With CSF and Plasma Biomarkers. Neurology. 2025. doi:10.1212/wnl.0000000000214040. PMID: 40921019.

BibTeX

@article{estellergauxax2025-40921019,
  author  = {Esteller-Gauxax, D. and Pérez Millan, A. and Sarto, J. and Puey, R. and Guillén Soley, N. and Tort-Merino, A. and Falgàs, N. and Borrego-Écija, S. and others},
  title   = {{α-Synuclein Seed Amplifications Assay in a Cohort With Cognitive Impairment: Performance and Interactions With CSF and Plasma Biomarkers}},
  journal = {Neurology},
  year    = {2025},
  doi     = {10.1212/wnl.0000000000214040},
  pmid    = {40921019},
  url     = {https://doi.org/10.1212/wnl.0000000000214040}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

We aimed to evaluate the diagnostic performance of αSAA for detecting αSyn in CSF for diagnosing dementia with Lewy bodies (DLB) in a clinical cohort of cognitively impaired individuals.
We explored how the coexistence of Alzheimer disease (AD) and αSyn pathology influences biomarker levels and clinical profiles.
This study contributes to the understanding of αSAA diagnostic performance for DLB and for detecting αSyn copathology in AD in a real-world memory clinic cohort, using both clinical and biomarker-based classifications.
Methods This was a retrospective, single-center, cross-sectional observational cohort study of cognitively impaired individuals who attended a tertiary memory clinic in Spain between 2009 and 2024.

Why it matters

This study assessed how well a spinal fluid test detects alpha-synuclein in people with cognitive impairment, including those who also have Alzheimer's pathology. It is a diagnostic study and does not provide a treatment or cure.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Study designcohort study
Participants337
Effect size95.7%; 91.6%; 99.8%
Evidence strengthModerate

How this study scored 59/100

Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	9 / 10	Tier 2 — leading specialty journal (Neurology)
Journal's citation record	4 / 4	Neurology: journal h-index 525 (OpenAlex, 2026-10-29)
Study design	7 / 12	A cohort study following people over time
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	2 / 4	337 participants
Effect reported	2 / 3	Effect reported as a number, without an interval or test
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	2 / 7	Cited 8 times (OpenAlex, 2026-10-10)
Citations per year	1 / 5	2.7 citations a year over 3 year(s) since 2025
Impact for its field and year	3 / 6	Cited 4.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	1 / 6	Cited by 1 other studies in this library
Still being cited	1 / 4	Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	2 / 4	Last-listed author Mircea Balasa: h-index 41 (OpenAlex, whole career)
Institution's track record	1 / 3	Universitat de Barcelona: institution h-index 1,049 (OpenAlex)
Multi-centre collaboration	2 / 3	OpenAlex lists 7 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 40921019)
Free to read	0 / 2	Behind a paywall — scores zero
Total	59 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 16.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Tau biomarkers

Also tagged “cerebrospinal”

821 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →